Mode
Text Size
Log in / Sign up
Phase 3 Completed N=52 Randomized Double-blind Treatment

Tranexamic Acid Dosing in Adult Spinal Deformity Surgery

Source: ClinicalTrials.gov NCT02053363 ↗
Enrolled (actual)
52
Serious AEs
9.6%
Results posted
Jun 2022
Primary outcomePrimary: Blood Loss — 2046; 1596 mL
◆ Published Evidence
Emerging
10citations · ~3 / year
Randomized, controlled trial of two tranexamic acid dosing protocols in adult spinal deformity surgery.
Spine deformity · 2022 · Likely link

Summary

The purpose of this study is to evaluate two dosing protocols for tranexamic acid (TXA), an anti-fibrinolytic used to decrease blood loss in adult patients undergoing complex, reconstructive spinal fusion surgeries.

Linked Publications

  • Randomized, controlled trial of two tranexamic acid dosing protocols in adult spinal deformity surgery.
    Spine deformity · 2022 · 10 citations · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Blood Loss
2046; 1596
SECONDARY
Red Blood Cell Transfusions
1259; 935
SECONDARY
Number of Patients Sustaining Intraoperative or 90 Day Complications
2; 3

Eligibility Criteria

Inclusion Criteria

  • Adult patients (ages 18-75) scheduled to undergo long segment (greater than 8 motion segments) posterior spinal fusion with instrumentation (PSF) for adult scoliosis

Exclusion Criteria

  • Patients with acquired defective color vision
  • Subarachnoid hemorrhage
  • Active intravascular clotting
  • Hypersensitivity to tranexamic acid or any of the ingredients
  • Patients who pre-donate autologous blood for intra- or post-operative use (Directed donor units are acceptable)
  • History of suspected blood disorders or abnormal coagulation laboratory results
  • Current anticoagulation therapy that cannot be interrupted
  • History of deep vein thrombosis (DVT)
  • Impaired renal function or creatinine clearance <60 ml/min
  • Pregnancy or women who are lactating/breastfeeding
  • Women on hormonal contraceptives
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02053363) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search